文献速递皮肤肿瘤

德国皮肤癌筛查项目参与者生存获益的行政数据队列研究

Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data.
PubMed 文献 · Br J Dermatol · 2021-10-04

基于德国萨克森州1 431 327人的医保数据开展回顾性队列研究(2010–2016年),比较参与筛查与未参与筛查的黑色素瘤患者死亡率。作者指出该获益可能源于健康筛查偏倚和/或过度诊断而非筛查本身。

要点

  • 筛查参与者局部区域转移、远处转移及全身治疗比例均更低
  • 获益可能来自健康筛查偏倚或过度诊断,不能直接归因于筛查

核心结论

  • 参与德国皮肤癌筛查项目的黑色素瘤患者死亡率低于未参与筛查者。
  • 该差异可能由健康筛查偏倚和/或过度诊断所致,而非筛查本身的效应。

研究设计与样本

  • 回顾性队列研究,基于德国萨克森州1 431 327人的匿名化健康保险数据,时间范围为2010–2016年。
  • 通过诊断、医疗操作和处方定义 prevalent 和 incident 黑色素瘤患者。
  • 筛查后2年内首次诊断黑色素瘤者归入干预组,采用相对生存和Cox回归评估死亡率差异。

主要发现

  • 共识别4552例prevalent黑色素瘤和2475例incident黑色素瘤患者。

临床怎么用

  • 解读筛查获益时需警惕健康筛查偏倚和过度诊断,不能仅凭观察性死亡率差异判定筛查有效。
  • 临床沟通中应向患者说明参与筛查与更好生存相关,但因果关系尚未确立。

局限性

  • 回顾性队列设计,可能存在健康筛查偏倚和/或过度诊断。
  • 基于行政医保数据,黑色素瘤定义依赖诊断、操作和处方记录。
  • 仅纳入德国萨克森州数据,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The German programme for skin cancer screening was established in 2008 with the aim of reducing skin cancer mortality. However, the effectiveness and risk-benefit ratio of the programme remain unclear. OBJECTIVES: To compare the mortality rates of patients with melanoma who participate in a screening programme to those who do not. METHODS: A retrospective cohort study, based on pseudonymized health insurance data of 1 431 327 individuals from Saxony, Germany, was conducted for the period 2010-2016. Patients with prevalent and incident melanoma were defined based on diagnosis, medical procedures and prescriptions. Patients who underwent screening and had a first diagnosis of melanoma within 2 years of screening were assigned to the intervention group. Relative survival and Cox regression were used to assess potential differences in mortality. RESULTS: We identified 4552 individuals with prevalent and 2475 individuals with incident melanoma. The percentage of screening participants (n = 1801) who had locoregional (4·2% vs. 13·5%) and/or distant metastases (4·3% vs. 8·0%), or who were treated with systemic anticancer therapies (11·6% vs. 21·8%) was lower vs. nonparticipants (n = 674). Screening participants had significantly better survival rates. The unadjusted Cox model gave a hazard ratio (HR) of 0·37 [95% confidence interval (CI) 0·30-0·46]. After adjusting for named confounders, the effect remained (HR 0·62, 95% CI 0·48-0·80). CONCLUSIONS: Patients who participated in the screening programme had lower mortality than those who had not undergone screening. However, these findings may result from a healthy screen bias and/or overdiagnosis associated with screening, and not from the screening itself.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Datzmann T, Schoffer O, Meier F, et al. Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data. Br J Dermatol. 2021. PMID: 34289097. doi:10.1111/bjd.20658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。